Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies
Novartis $NVS has been noticeably absent from the center ring of PD-1/L1 research, quietly advancing its own checkpoint as an in-house asset to match up with a growing pipeline of cancer therapies. But that doesn’t mean that newly promoted CEO Vas Narasimhan hasn’t been thinking a lot about the pharma giant’s development strategy or what it has to do to position itself as the industry faces readouts on a tsunami of more than 1,000 combination studies now in the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
